The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, S. C.
Right arrow Articles by Eliopoulos, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, S. C.
Right arrow Articles by Eliopoulos, A. G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cervical Cancer
The Journal of Immunology, 2005, 174: 41-50.
Copyright © 2005 by The American Association of Immunologists

Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis1

Seran C. Hill*, Sarah J. Youde{ddagger}, Stephen Man{ddagger}, Glyn R. Teale*,{dagger}, Amanda J. Baxendale*, Andrew Hislop*, Clare C. Davies*, David M. Luesley{dagger}, Anna M. Blom§, Alan B. Rickinson*, Lawrence S. Young* and Aristides G. Eliopoulos2,3,*

* Cancer Research UK Institute for Cancer Studies and Medical Research Council Centre for Immune Regulation, University of Birmingham Medical School, and {dagger} City Hospital National Health Service Trust, Birmingham, United Kingdom; {ddagger} Section of Infection and Immunity, University of Wales College of Medicine, Cardiff, United Kingdom; and § Department of Clinical Chemistry, Lund University, The Wallenberg Laboratory, University Hospital, Malmo, Sweden

In this study, we describe the expression and function of CD40, a TNF receptor family member, in cervical carcinomas. CD40 was present at very low levels in normal cervical epithelium but was overexpressed in human papillomavirus-infected lesions and advanced squamous carcinomas of the cervix. The stimulation of CD40-positive cervical carcinoma cell lines with soluble CD40L (CD154) resulted in activation of the NF-{kappa}B and MAPK signaling pathways and up-regulation of cell surface markers and intracellular molecules associated with Ag processing and presentation. Concomitantly, the CD154-induced activation of CD40 in carcinoma cells was found to directly influence susceptibility to CTL-mediated killing. Thus, CD40 stimulation in cervical carcinoma cell lines expressing a TAP-dependent human papillomavirus 16 E6 Ag epitope resulted in their enhanced killing by specific CTLs. However, CD154 treatment of carcinoma cells expressing proteasome-dependent but TAP-independent Ags from the EBV-encoded BRLF1 and BMLF1 failed to increase tumor cell lysis by specific CTLs. Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis. Taken together, these observations demonstrate the functional expression of CD40 in epithelial tumors of the cervix and support the clinical exploitation of the CD40 pathway for the treatment of cervical cancer through its multiple effects on tumor cell growth, apoptosis, and immune recognition.




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
A. Moschonas, M. Kouraki, P. G. Knox, E. Thymiakou, D. Kardassis, and A. G. Eliopoulos
CD40 Induces Antigen Transporter and Immunoproteasome Gene Expression in Carcinomas via the Coordinated Action of NF-{kappa}B and of NF-{kappa}B-Mediated De Novo Synthesis of IRF-1
Mol. Cell. Biol., October 15, 2008; 28(20): 6208 - 6222.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Bergmann and P. P. Pandolfi
Giving blood: a new role for CD40 in tumorigenesis
J. Exp. Med., October 30, 2006; 203(11): 2409 - 2412.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. C. Davies, T. W. Mak, L. S. Young, and A. G. Eliopoulos
TRAF6 Is Required for TRAF2-Dependent CD40 Signal Transduction in Nonhemopoietic Cells
Mol. Cell. Biol., November 15, 2005; 25(22): 9806 - 9819.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.